Form 4: Entera Bio CFO Receives Equity Grant in Lieu of Bonus

Entera Bio CFO Dana Yaacov-Garbeli was granted 58,394 restricted stock units in lieu of a cash bonus.

Summary

• Dana Yaacov-Garbeli, Chief Financial Officer of Entera Bio Ltd., received a grant of 58,394 stock-settled restricted stock units (RSUs).
• The grant was approved by the Board of Directors on May 7, 2026.
• The RSUs were issued in lieu of a cash bonus previously owed to the CFO.
• The units vest ratably on a quarterly basis over a one-year period starting May 1, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event reflecting standard executive compensation practices rather than a change in company performance.

Positives

• The issuance of equity in lieu of cash preserves the company's cash reserves.
• The grant aligns the CFO's interests with long-term shareholder value through a one-year vesting schedule.

Negatives

• The transaction results in minor dilution to existing shareholders.

Risks

• Market volatility could impact the future value of the equity granted to the executive.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the equity compensation transaction.

Management Comments

• The grant was awarded in lieu of a cash bonus the Reporting Person was otherwise entitled to.

Industry Context

StockSavvy.ai notes that it is common practice for small-cap biotechnology firms to utilize equity-based compensation to preserve cash for R&D and clinical trial operations.

Comparison to Industry Standards

• The use of stock-settled RSUs in lieu of cash is a standard practice for cash-constrained biotech companies to manage liquidity.
• The one-year vesting period is relatively short compared to standard three-to-four-year executive equity vesting schedules.

Related Party Transactions

• The reporting person holds a 33.33% interest in A2Z Counseling Ltd., which holds 171,441 shares of the issuer.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Quarterly vesting of the granted RSUs over the next 12 months.

Key Dates

Keywords

Entera Bio, ENTX, Insider Trading, Form 4, Equity Compensation, CFO